about
The cell biology of HIV-1 and other retrovirusesHuman APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1Extracellular vesicles during Herpes Simplex Virus type 1 infection: an inquireCrystal Structure of the DNA Cytosine Deaminase APOBEC3F: The Catalytically Active and HIV-1 Vif-Binding DomainGreater ethnic diversity correlates with lower HIV prevalence in Africa: justification for an alloimmunity vaccine.HIV-1 modulates the tRNA pool to improve translation efficiency.Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression.Host restriction factors in retroviral infection: promises in virus-host interaction.Current topics in prevention of human T-cell leukemia virus type i infection: NF-kappa B inhibitors and APOBEC3.Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.Insights into the motif preference of APOBEC3 enzymes.APOBECs and virus restriction.Host apolipoprotein B messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus.Exosomes packaging APOBEC3G confer human immunodeficiency virus resistance to recipient cells.Sp1 and Sp3 regulate basal transcription of the human APOBEC3G gene.Differential virus restriction patterns of rhesus macaque and human APOBEC3A: implications for lentivirus evolutionStrategy of Human Cytomegalovirus To Escape Interferon Beta-Induced APOBEC3G Editing Activity
P2860
Q21245199-155FF782-F188-4C34-AFF6-4622A8769C90Q24655541-4588C0DF-967A-4D31-BB87-8065FEF8652CQ26751440-D1006A63-CC5C-46EF-9F65-3A0CFC3091E7Q27678176-E71E0B08-A24E-46B2-81F1-6DE04C16AE33Q30429668-845FBE2E-33D1-4B18-8A98-D389C82B8E49Q34994062-9339E510-1F78-4046-817C-2F45896FAE39Q35850696-726D9F4F-AB19-4943-A4F3-72CBC4D050AFQ36548179-6F0EAA0E-3DDE-471F-8385-7CCABE670F18Q37198681-A3CCDD2C-4BA9-4B67-86DC-ADA6C4E0F3C9Q37504507-00E9E73A-FD07-4DBE-91D3-646418B03D55Q37539036-CB1FFADE-8269-4799-919E-58C490F15332Q38394187-2DE631F1-044F-4F14-9299-2E93B3787EA7Q39561115-D42E8408-CBF8-4F4E-97FE-88B8D60FF1BBQ39920895-03F038C4-8C18-474F-B3ED-40292EB4BDB1Q40129583-24D4DDDF-24F6-431E-87D2-102DB7FD3CABQ42041441-639A8979-B5D0-4765-A2F3-9F786D81BF41Q58866812-B9BDD862-1778-48C8-9084-4CDA12274DEA
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականին հրատարակուած գիտական յօդուած
@hyw
2005 թվականին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
APOBEC3G & HTLV-1: inhibition without deamination
@ast
APOBEC3G & HTLV-1: inhibition without deamination
@en
APOBEC3G & HTLV-1: inhibition without deamination
@nl
type
label
APOBEC3G & HTLV-1: inhibition without deamination
@ast
APOBEC3G & HTLV-1: inhibition without deamination
@en
APOBEC3G & HTLV-1: inhibition without deamination
@nl
prefLabel
APOBEC3G & HTLV-1: inhibition without deamination
@ast
APOBEC3G & HTLV-1: inhibition without deamination
@en
APOBEC3G & HTLV-1: inhibition without deamination
@nl
P2860
P3181
P356
P1433
P1476
APOBEC3G & HTLV-1: inhibition without deamination
@en
P2093
Klaus Strebel
P2860
P2888
P3181
P356
10.1186/1742-4690-2-37
P407
P577
2005-01-01T00:00:00Z
P5875
P6179
1033168099